BI 655130

Drug Profile

BI 655130

Alternative Names: BI655130

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pustular psoriasis

Most Recent Events

  • 24 Apr 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in South Korea (NCT03123094)
  • 24 Apr 2017 Boehringer Ingelheim plans a proof-of-concept phase II trial for Ulcerative colitis in Denmark, Ireland, Netherlands, Norway, Spain and United Kingdom (NCT03123120; EudraCT2016-004572-21)
  • 07 Apr 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Belgium (NCT03100903)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top